[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism]

Nihon Rinsho. 2002 Feb:60 Suppl 2:439-44.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Amoxicillin / administration & dosage*
  • Aryl Hydrocarbon Hydroxylases*
  • Benzimidazoles / administration & dosage*
  • Benzimidazoles / pharmacokinetics
  • Clarithromycin / administration & dosage
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 Enzyme System / genetics*
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / pharmacokinetics
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Lansoprazole
  • Mixed Function Oxygenases / genetics*
  • Omeprazole / administration & dosage*
  • Omeprazole / analogs & derivatives*
  • Omeprazole / pharmacokinetics
  • Pharmacogenetics
  • Polymorphism, Genetic*
  • Proton Pump Inhibitors*
  • Rabeprazole
  • Treatment Failure

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Lansoprazole
  • Rabeprazole
  • Amoxicillin
  • Cytochrome P-450 Enzyme System
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Clarithromycin
  • Omeprazole